What did @midlifeinvintage actually say?
She made a specific and personal claim: her pain from Hypermobility Spectrum Disorder (HSD) has gotten worse since entering perimenopause. She also described HSD as being "in the same family of connective tissue disorders as Ehlers-Danlos," and listed symptoms including joint instability, gastrointestinal problems, and autonomic dysfunction. She was careful to say she is not a physician and spoke only from personal experience.
Credit where it is due: this is a more honest framing than most health content on Instagram. She did not claim causation, did not sell anything, and did not recommend a treatment protocol. The core observation, that perimenopausal hormone shifts seem to correlate with worsening connective tissue symptoms, is actually something researchers have been paying attention to for years.
Does the science back this up?
Yes, more than most people realize. The link between estrogen, connective tissue integrity, and pain sensitivity is real and reasonably well-supported. Estrogen receptors are found in ligaments, tendons, and cartilage, and declining estrogen during perimenopause affects collagen synthesis and joint laxity.
A 2021 paper by Shiel and colleagues in the American Journal of Medical Genetics examined symptom trajectories in hypermobile Ehlers-Danlos syndrome (hEDS) and HSD patients and found that a significant proportion of women reported symptom worsening around hormonal transition periods, including perimenopause. Separately, research by Castori et al. (2012, American Journal of Medical Genetics) established that autonomic dysfunction and gastrointestinal dysmotility are common in HSD and hEDS, which she correctly identified as part of her symptom picture. The estrogen-collagen connection has also been documented by Liu et al. (2017, Osteoporosis International), who found that estrogen withdrawal reduces collagen cross-linking in musculoskeletal tissue.
None of this proves her perimenopause caused her flare. But the biological mechanism is plausible and the clinical observation is consistent with what researchers are finding.
What did they get wrong (or right)?
The HSD-Ehlers-Danlos framing is mostly right but slightly loose. She described HSD as being "in the same family" as Ehlers-Danlos, which is a reasonable lay description. Technically, the 2017 International Classification by Malfait et al. positions HSD and hEDS as related but distinct diagnoses, separated largely because hEDS requires additional systemic criteria. This is a minor simplification, not a harmful one.
Her symptom list, including joint instability, gastrointestinal problems, and autonomic dysfunction such as temperature dysregulation and blood pressure variability, is clinically accurate for HSD. These are well-documented features. She even used the correct term, autonomic dysfunction, and acknowledged she had to look it up. That is transparency, not ignorance.
What she did not address, and this is worth noting, is that testosterone also plays a role in connective tissue health and pain modulation. Since this content is tagged under TRT, it is worth knowing that low testosterone has been associated with increased pain sensitivity in some studies. But she never claimed TRT was a solution, so this is context she left out, not a claim she got wrong.
What should you actually know?
If you have HSD or hypermobile EDS and you are approaching perimenopause, this is a conversation worth having with a clinician who understands both conditions, and those are not always easy to find. Rheumatologists familiar with connective tissue disorders and menopause specialists often exist in separate silos.
Hormone therapy has not been studied as a specific treatment for HSD symptom management, so anyone claiming it will definitively fix your joint pain is getting ahead of the evidence. That said, there is a reasonable biological argument that estrogen support may help preserve collagen integrity, and some clinicians do consider this in the clinical picture. Testosterone, too, has shown some promise in pain modulation research. Traish et al. (2018, Journal of Sexual Medicine) reviewed androgen receptor distribution in musculoskeletal tissue and suggested androgens contribute to muscle and tendon maintenance, though this research is not HSD-specific.
The bigger takeaway is that women with pre-existing connective tissue conditions are an underserved population in menopause research. Her experience of being dismissed for years before a diagnosis, which she alludes to in the caption, fits a documented pattern. A 2019 survey by the Ehlers-Danlos Society found that the average diagnostic delay for hEDS and HSD was over ten years, with women disproportionately affected.
Bottom line
This video is honest, appropriately caveated, and describes a real clinical phenomenon. The perimenopause-to-worsening-hypermobility connection has biological plausibility and emerging research support. She did not oversell it, did not diagnose anyone, and did not push a product. For Instagram health content, that is a higher bar than most creators clear. The gaps in her explanation are gaps in the research itself, not errors in her presentation.